In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. - Wikidata - awgldk - TriplyDB

In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.

In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.

http://www.wikidata.org/entity/Q37622756

about

A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD Medication use and the risk of motor vehicle collision in West Virginia drivers 65 years of age and older: a case-crossover study.Consequences of renal failure on non-renal clearance of drugs.Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.

P2860

Q28087621-DF7D48E4-C4B5-4D14-BAE2-E7444460FFFA Q35958160-FC90DC06-7C5E-494A-AB80-BC7E73B1DE83 Q38214827-DD47DD7A-B5A6-45E8-8B15-E902D065F9A1 Q38699135-F818DAB5-8DF0-4F8E-9348-C29DE98FE7BB Q46675919-55C4DFBA-C91B-4512-AB3F-D161C225C07B Q50108575-FF5D4B15-0724-414A-B904-FFE59C626327 Q53233045-7564144A-6C4C-4407-8EDF-B1AA95093FA8

P2860

In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.

http://www.wikidata.org/entity/Q37622756

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

In vivo alterations in drug me ...... with chronic kidney diseases.

@en

In vivo alterations in drug me ...... with chronic kidney diseases.

@nl

type

label

In vivo alterations in drug me ...... with chronic kidney diseases.

@en

In vivo alterations in drug me ...... with chronic kidney diseases.

@nl

prefLabel

In vivo alterations in drug me ...... with chronic kidney diseases.

@en

In vivo alterations in drug me ...... with chronic kidney diseases.

@nl

P1433

Q37622756-815C13F9-431F-4B1E-851A-82012366DE4C

P1476

Q37622756-1F4C1B28-73AC-489B-B344-A78850D6BB46

P2093

Q37622756-3274FCB3-75E2-435C-A9D1-E81BF6E31CC2

Q37622756-60D4B732-E603-4503-87EE-F6784B5FB581

Q37622756-6728BEB9-7055-4DDD-9E94-09F312CA326C

Q37622756-85306ED9-EB20-4A58-858E-F2B4327E91AC

Q37622756-8CFAA01A-88CB-42BA-9084-18F9B1F6E923

Q37622756-BFDA015E-010D-414C-872A-A0C9D08164C4

Q37622756-C7356F2A-F0FB-44DC-8CC1-24252435AD32

P2860

Q37622756-03B0D42D-2D5C-461A-9FB0-72A7AC106765

Q37622756-09912DD3-8393-42D7-84A8-CDC0A412F703

Q37622756-0AF54F0C-E96A-4B4F-AF40-19D77DE10C69

Q37622756-146AF11A-E5DF-4382-9B1A-4B2C45E930B2

Q37622756-16EAD097-AEA2-4DE0-8121-E384169E432B

Q37622756-200BE2F2-35E7-4C86-9CFE-BE706D085292

Q37622756-3ABFACD9-975C-4164-B728-41F5CA5FC9F9

Q37622756-3E2D7418-CDF9-4FA8-959B-B063404696B2

Q37622756-4198553A-A662-4EDD-806A-62A51B4BE57B

Q37622756-42C05064-DC8B-47C1-A386-003D69ED98E1

P304

Q37622756-67B314D2-09EB-4A9A-9FC9-129E1878D487

P31

Q37622756-FC4352D0-391F-4AC4-B313-586173E4F683

P356

Q37622756-49F04B5A-5059-48B3-ACC0-BE54B05D5017

P407

Q37622756-6286964E-E3F4-4179-ADFD-3EA2CC7AE5E6

P433

Q37622756-E3A30521-B429-4B60-BA2F-E8D7DB1BB99F

P478

Q37622756-608557EE-C553-487E-8FB5-FF292BF6E0CD

P50

Q37622756-03494217-CA6A-4CA3-90DD-59C3DC804676

Q37622756-FE42FADC-6A8C-455A-9405-904CEC0DC856

P577

Q37622756-94DCDBF6-2763-45F1-8740-13F267AFDCC0

P698

Q37622756-19AF1F65-9F4D-4DAA-97EB-EDE94FC72B77

P932

Q37622756-119C96E3-A376-4DA1-8B9A-DB2B752D4EF1

P356

P1433

Pharmacotherapy

P1476

In vivo alterations in drug me ...... s with chronic kidney diseases

@en

P2093

Brittney V Roberts

http://www.w3.org/2001/XMLSchema#string

Jinzhao Wang

http://www.w3.org/2001/XMLSchema#string

Mary Anne Dooley

http://www.w3.org/2001/XMLSchema#string

Mary K La

http://www.w3.org/2001/XMLSchema#string

Melanie S Joy

http://www.w3.org/2001/XMLSchema#string

Ronald J Falk

http://www.w3.org/2001/XMLSchema#string

Thomas D Nolin

http://www.w3.org/2001/XMLSchema#string

P2860

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider

Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease

Prevalence of chronic kidney disease in the United States

Prediction of creatinine clearance from serum creatinine

Membrane transporters in drug development

Regulation of cytochrome p450 by inflammatory mediators: why and how?

Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates.

Pharmacokinetics of mycophenolic acid in patients with lupus nephritis.

Food-drug interactions via human cytochrome P450 3A (CYP3A).

P304

114-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1347

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Reginald F. Frye

P577

2013-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24038489

http://www.w3.org/2001/XMLSchema#string

P932

3945423

http://www.w3.org/2001/XMLSchema#string